These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 9254895

  • 21. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
    Szepesházi K, Halmos G, Schally AV, Arencibia JM, Groot K, Vadillo-Buenfil M, Rodriguez-Martin E.
    J Cancer Res Clin Oncol; 1999; 125(8-9):444-52. PubMed ID: 10480336
    [Abstract] [Full Text] [Related]

  • 22. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
    Pinski J, Halmos G, Schally AV.
    Cancer Lett; 1993 Jul 30; 71(1-3):189-96. PubMed ID: 8103419
    [Abstract] [Full Text] [Related]

  • 23. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT.
    Cancer Res; 1992 May 01; 52(9):2538-44. PubMed ID: 1568223
    [Abstract] [Full Text] [Related]

  • 24. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.
    Miyazaki M, Lamharzi N, Schally AV, Halmos G, Szepeshazi K, Groot K, Cai RZ.
    Eur J Cancer; 1998 Apr 01; 34(5):710-7. PubMed ID: 9713279
    [Abstract] [Full Text] [Related]

  • 25. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
    Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T.
    Acta Oncol; 1994 Apr 01; 33(6):693-701. PubMed ID: 7946450
    [Abstract] [Full Text] [Related]

  • 26. Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.
    Qin Y, Halmos G, Cai RZ, Szoke B, Ertl T, Schally AV.
    J Cancer Res Clin Oncol; 1994 Apr 01; 120(9):519-28. PubMed ID: 8045917
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.
    Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, Szepeshazi K.
    Proc Natl Acad Sci U S A; 2002 Mar 19; 99(6):3836-41. PubMed ID: 11891317
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats.
    Pinski J, Yano T, Schally AV.
    Neuroendocrinology; 1992 Dec 19; 56(6):831-7. PubMed ID: 1369591
    [Abstract] [Full Text] [Related]

  • 36. Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II, Jungwirth et al., Eur J Cancer 1997, 33(7), 1141-1148.
    Limonta P, Pratesi G, Moretti RM, Montagnani Marelli M, Motta M, Dondi D.
    Eur J Cancer; 1998 Jun 19; 34(7):1134-6. PubMed ID: 9849469
    [No Abstract] [Full Text] [Related]

  • 37. Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.
    Szepshazi K, Halmos G, Groot K, Schally AV.
    Int J Pancreatol; 1994 Jun 19; 16(2-3):141-9. PubMed ID: 7868940
    [Abstract] [Full Text] [Related]

  • 38. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095).
    Sotomayor S, Muñoz-Moreno L, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM.
    Int J Cancer; 2010 Oct 15; 127(8):1813-22. PubMed ID: 20099275
    [Abstract] [Full Text] [Related]

  • 39. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
    Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL, Hohla F.
    Cell Cycle; 2012 Jul 01; 11(13):2518-25. PubMed ID: 22751419
    [Abstract] [Full Text] [Related]

  • 40. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
    Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV.
    Prostate; 1992 Jul 01; 20(4):297-310. PubMed ID: 1351672
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.